Testing Foquest for ADHD in adults 65 and older
Part of Mental health clinical trials.
This trial tests if the medication Foquest can help treat ADHD symptoms in adults aged 65 and older. It aims to see if it's safe and effective for this age group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 65 years old or older
- You must have a diagnosis of ADHD (any type: inattentive, hyperactive/impulsive, or combined)
- You must score at least 14 on a screening scale for ADHD symptoms and 24 on another scale at the start
- You must not have certain heart conditions, uncontrolled high blood pressure, or a history of stroke
- You must not have bipolar disorder, active suicidal thoughts, or substance use disorder
- You must not have had a bad reaction to methylphenidate (the drug in Foquest) in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if Jornay PM, a long-acting ADHD medication, helps control symptoms, focus, and emotions throughout the day and into the early evening in adults with ADHD. It is an open-label study, meaning everyone knows they are getting the medication, and then they are randomly assigned to different observation groups.
This study compares stimulant and non-stimulant ADHD medicines in kids who have not taken ADHD medication before. It also studies how these treatments affect brain “reward” processes, which may be linked to substance-use risk.
This trial checks whether a “NIH Toolbox” set of child-friendly tests can detect changes when stimulant medicine is used for ADHD. It may help doctors better measure how well stimulant treatment is working in people with intellectual disability.
This trial tests a new extended-release medication called Onyda XR (clonidine) in children aged 6 to 12 who have both ADHD and Oppositional Defiant Disorder. The goal is to see if it helps with symptoms like inattention, hyperactivity, and defiant behavior, and if it is safe.
This study tests an investigational medication for adults with attention deficit hyperactivity disorder (ADHD). It aims to see if this new drug helps reduce ADHD symptoms compared to a placebo.
This trial tests whether methylphenidate (a stimulant medicine) helps adults with attention-deficit/hyperactivity disorder (ADHD). It is checking safety and effectiveness for people who can take the immediate-release form of the medicine.
Hear when a new ADHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.